REM sleep behaviour disorder

Yves Dauvilliers, Carlos H. Schenck, Ronald B. Postuma, Alex Iranzo, Pierre Herve Luppi, Giuseppe Plazzi, Jacques Montplaisir, Bradley F Boeve

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia that is characterized by loss of muscle atonia during REM sleep (known as REM sleep without atonia, or RSWA) and abnormal behaviours occurring during REM sleep, often as dream enactments that can cause injury. RBD is categorized as either idiopathic RBD or symptomatic (also known as secondary) RBD; the latter is associated with antidepressant use or with neurological diseases, especially α-synucleinopathies (such as Parkinson disease, dementia with Lewy bodies and multiple system atrophy) but also narcolepsy type 1. A clinical history of dream enactment or complex motor behaviours together with the presence of muscle activity during REM sleep confirmed by video polysomnography are mandatory for a definite RBD diagnosis. Management involves clonazepam and/or melatonin and counselling and aims to suppress unpleasant dreams and behaviours and improve bedpartner quality of life. RSWA and RBD are now recognized as manifestations of an α-synucleinopathy; most older adults with idiopathic RBD will eventually develop an overt neurodegenerative syndrome. In the future, studies will likely evaluate neuroprotective therapies in patients with idiopathic RBD to prevent or delay α-synucleinopathy-related motor and cognitive decline.

Original languageEnglish (US)
Article number19
JournalNature Reviews Disease Primers
Volume4
Issue number1
DOIs
StatePublished - Dec 1 2018

Fingerprint

REM Sleep Behavior Disorder
REM Sleep
Sleep
Parasomnias
Multiple System Atrophy
Clonazepam
Lewy Body Disease
Muscles
Polysomnography
Melatonin
Antidepressive Agents
Parkinson Disease
Counseling
Quality of Life

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Dauvilliers, Y., Schenck, C. H., Postuma, R. B., Iranzo, A., Luppi, P. H., Plazzi, G., ... Boeve, B. F. (2018). REM sleep behaviour disorder. Nature Reviews Disease Primers, 4(1), [19]. https://doi.org/10.1038/s41572-018-0016-5

REM sleep behaviour disorder. / Dauvilliers, Yves; Schenck, Carlos H.; Postuma, Ronald B.; Iranzo, Alex; Luppi, Pierre Herve; Plazzi, Giuseppe; Montplaisir, Jacques; Boeve, Bradley F.

In: Nature Reviews Disease Primers, Vol. 4, No. 1, 19, 01.12.2018.

Research output: Contribution to journalReview article

Dauvilliers, Y, Schenck, CH, Postuma, RB, Iranzo, A, Luppi, PH, Plazzi, G, Montplaisir, J & Boeve, BF 2018, 'REM sleep behaviour disorder', Nature Reviews Disease Primers, vol. 4, no. 1, 19. https://doi.org/10.1038/s41572-018-0016-5
Dauvilliers Y, Schenck CH, Postuma RB, Iranzo A, Luppi PH, Plazzi G et al. REM sleep behaviour disorder. Nature Reviews Disease Primers. 2018 Dec 1;4(1). 19. https://doi.org/10.1038/s41572-018-0016-5
Dauvilliers, Yves ; Schenck, Carlos H. ; Postuma, Ronald B. ; Iranzo, Alex ; Luppi, Pierre Herve ; Plazzi, Giuseppe ; Montplaisir, Jacques ; Boeve, Bradley F. / REM sleep behaviour disorder. In: Nature Reviews Disease Primers. 2018 ; Vol. 4, No. 1.
@article{cc846f53e94b4faa9a8623e2af553a08,
title = "REM sleep behaviour disorder",
abstract = "Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia that is characterized by loss of muscle atonia during REM sleep (known as REM sleep without atonia, or RSWA) and abnormal behaviours occurring during REM sleep, often as dream enactments that can cause injury. RBD is categorized as either idiopathic RBD or symptomatic (also known as secondary) RBD; the latter is associated with antidepressant use or with neurological diseases, especially α-synucleinopathies (such as Parkinson disease, dementia with Lewy bodies and multiple system atrophy) but also narcolepsy type 1. A clinical history of dream enactment or complex motor behaviours together with the presence of muscle activity during REM sleep confirmed by video polysomnography are mandatory for a definite RBD diagnosis. Management involves clonazepam and/or melatonin and counselling and aims to suppress unpleasant dreams and behaviours and improve bedpartner quality of life. RSWA and RBD are now recognized as manifestations of an α-synucleinopathy; most older adults with idiopathic RBD will eventually develop an overt neurodegenerative syndrome. In the future, studies will likely evaluate neuroprotective therapies in patients with idiopathic RBD to prevent or delay α-synucleinopathy-related motor and cognitive decline.",
author = "Yves Dauvilliers and Schenck, {Carlos H.} and Postuma, {Ronald B.} and Alex Iranzo and Luppi, {Pierre Herve} and Giuseppe Plazzi and Jacques Montplaisir and Boeve, {Bradley F}",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41572-018-0016-5",
language = "English (US)",
volume = "4",
journal = "Nature Reviews Disease Primers",
issn = "2056-676X",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - REM sleep behaviour disorder

AU - Dauvilliers, Yves

AU - Schenck, Carlos H.

AU - Postuma, Ronald B.

AU - Iranzo, Alex

AU - Luppi, Pierre Herve

AU - Plazzi, Giuseppe

AU - Montplaisir, Jacques

AU - Boeve, Bradley F

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia that is characterized by loss of muscle atonia during REM sleep (known as REM sleep without atonia, or RSWA) and abnormal behaviours occurring during REM sleep, often as dream enactments that can cause injury. RBD is categorized as either idiopathic RBD or symptomatic (also known as secondary) RBD; the latter is associated with antidepressant use or with neurological diseases, especially α-synucleinopathies (such as Parkinson disease, dementia with Lewy bodies and multiple system atrophy) but also narcolepsy type 1. A clinical history of dream enactment or complex motor behaviours together with the presence of muscle activity during REM sleep confirmed by video polysomnography are mandatory for a definite RBD diagnosis. Management involves clonazepam and/or melatonin and counselling and aims to suppress unpleasant dreams and behaviours and improve bedpartner quality of life. RSWA and RBD are now recognized as manifestations of an α-synucleinopathy; most older adults with idiopathic RBD will eventually develop an overt neurodegenerative syndrome. In the future, studies will likely evaluate neuroprotective therapies in patients with idiopathic RBD to prevent or delay α-synucleinopathy-related motor and cognitive decline.

AB - Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia that is characterized by loss of muscle atonia during REM sleep (known as REM sleep without atonia, or RSWA) and abnormal behaviours occurring during REM sleep, often as dream enactments that can cause injury. RBD is categorized as either idiopathic RBD or symptomatic (also known as secondary) RBD; the latter is associated with antidepressant use or with neurological diseases, especially α-synucleinopathies (such as Parkinson disease, dementia with Lewy bodies and multiple system atrophy) but also narcolepsy type 1. A clinical history of dream enactment or complex motor behaviours together with the presence of muscle activity during REM sleep confirmed by video polysomnography are mandatory for a definite RBD diagnosis. Management involves clonazepam and/or melatonin and counselling and aims to suppress unpleasant dreams and behaviours and improve bedpartner quality of life. RSWA and RBD are now recognized as manifestations of an α-synucleinopathy; most older adults with idiopathic RBD will eventually develop an overt neurodegenerative syndrome. In the future, studies will likely evaluate neuroprotective therapies in patients with idiopathic RBD to prevent or delay α-synucleinopathy-related motor and cognitive decline.

UR - http://www.scopus.com/inward/record.url?scp=85052620345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052620345&partnerID=8YFLogxK

U2 - 10.1038/s41572-018-0016-5

DO - 10.1038/s41572-018-0016-5

M3 - Review article

C2 - 30166532

AN - SCOPUS:85052620345

VL - 4

JO - Nature Reviews Disease Primers

JF - Nature Reviews Disease Primers

SN - 2056-676X

IS - 1

M1 - 19

ER -